GlassScriptPhysician profile
Anthony J Weido
NPI 1679570584
$31,276.26
in general payments reported to CMS, 2019-2025
31 companies · $1,513 in 2025
The $1,513 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $300 · 2021: $490 · 2022: $560 · 2023: $721 · 2024: $878 · 2025: $1,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,102 · Consulting Fee: $9.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,102.19 |
| Consulting Fee | $9.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27,142.46 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $715.27 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Csl Behring | $576.44 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $519.01 | 2021-2025 | Cuvitru, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $239.60 | 2019-2025 | Dupixent |
| Kaleo, INC. | $228.82 | 2019-2024 | Auvi-Q |
| Pfizer INC. | $193.65 | 2019-2025 | |
| Genentech USA, INC. | $162.62 | 2024-2025 | Xolair |
| Genzyme Corporation | $145.39 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $145.16 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $143.44 | 2025 | Neffy |
| Optinose US, INC. | $143.12 | 2019-2022 | |
| Grifols USA, LLC | $139.88 | 2019-2025 | Xembify |
| Octapharma USA, INC. | $99.37 | 2025 | Panzyga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.85 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $82.57 | 2022-2024 | Adbry |
| Ionis Pharmaceuticals, INC. | $69.15 | 2025 | Dawnzera |
| Blueprint Medicines Corporation | $66.70 | 2024 | Ayvakit |
| Pharming Healthcare, INC. | $59.51 | 2021-2024 | Ruconest |
| Amgen INC. | $50.16 | 2022 | |
| Aimmune Therapeutics, INC. | $35.15 | 2021-2022 | |
| Shire North American Group INC | $34.95 | 2019 | |
| Sunovion Pharmaceuticals INC. | $29.26 | 2019 | |
| Gc Biopharma USA, INC. | $25.51 | 2025 | Alyglo |
| Alk-Abello, INC | $25.29 | 2021 | |
| Azurity Pharmaceuticals, INC. | $22.65 | 2025 | Horizant |
| Verona Pharma, INC. | $22.07 | 2025 | Ohtuvayre |
| Hikma Pharmaceuticals USA | $19.38 | 2024 | Ryaltris |
| Galderma Laboratories, L.P. | $18.93 | 2025 | Nemluvio |
| Teva Pharmaceuticals USA, INC. | $15.33 | 2019 | |
| Adma Biomanufacturing LLC | $9.57 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Weido listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.